Market Overview

UPDATE: Jefferies Lowers PT on AbbVie on Attractive Entry Point Potential

Share:
Related
8 Of The Biggest Biotech Announcements Out Of The 2016 ASH Meeting
Gilead Responds To CMS Blog Highlighting High Cost Of Harvoni: Most Payers Receive Substantial Discounts Off The List Price
Why Is AbbVie A Strong Buy In 2016? Part 1 (Seeking Alpha)

In a report published Friday, Jefferies analyst Jeffrey Holford reiterated a Buy rating on AbbVie (NYSE: ABBV), but lowered the price target from $54.00 to $51.00.

In the report, Jefferies noted, “We reiterate Novartis as our Top European and Global Pick with positive growth inflection potential in 2014 and significant restructuring optionality being key drivers. Abbott is our Top US Pick for similar reasons. We highlight Roche, Sanofi and AbbVie as potentially offering particularly attractive entry points following the recent sell-off. AstraZeneca is now our Least Preferred stock.”

AbbVie closed on Thursday at $43.04.

Latest Ratings for ABBV

DateFirmActionFromTo
Nov 2016CitigroupDowngradesBuyNeutral
Oct 2016Credit SuisseDowngradesOutperformNeutral
Oct 2016Leerink SwannInitiates Coverage OnMarket Perform

View More Analyst Ratings for ABBV
View the Latest Analyst Ratings

Posted-In: Jefferies Jeffrey HolfordAnalyst Color Price Target Analyst Ratings

 

Related Articles (ABBV)

View Comments and Join the Discussion!